Papillomavirus and cancers: should we extend vaccination to boys in France? | Zendy

Laurent Abramowitz | Zendy; Philippe Descamps | Zendy; François Denis | Zendy; MarieAliette Dommergues | Zendy; Pierre Pradat | Zendy; Jean Lacau St Guily | Zendy; P. Judlin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Papillomavirus and cancers: should we extend vaccination to boys in France?

Author(s) -

Laurent Abramowitz,

Philippe Descamps,

François Denis,

MarieAliette Dommergues,

Pierre Pradat,

Jean Lacau St Guily,

P. Judlin

Publication year - 2016

Publication title -

journal of public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.916

H-Index - 82

eISSN - 1741-3850

pISSN - 1741-3842

DOI - 10.1093/pubmed/fdw099

Subject(s) - vaccination , anal cancer , medicine , genital warts , penile cancer , human papillomavirus , family medicine , cancer , hpv vaccines , public health , gardasil , marketing authorization , cervical cancer , gynecology , hpv infection , immunology , pathology , bioinformatics , biology

In 2006, the HPV (Human papillomavirus) 6/11/16/18 quadrivalent vaccine was approved by the European Medicines Agency and obtained its marketing authorization in both girls and boys. Currently, the French guidelines recommend and refund vaccination of girls aged 11 to 14 with a catch-up program for females from 15 to 19 years old.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research